Skip to main content

Table 4 Cost-effectiveness analysis results

From: Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Drug

Stable days per patient

Days in relapse per patient

Average visits to the emergency room per patient

Average number of hospitalizations per patient

Economic conclusion*

PP-LAI

325.0

39.0

0.15

0.28

dominant

RIS-LAI

318.6

45.4

0.17

0.33

dominated

  1. LAI long acting injectable, PP paliperidone palmitate, RIS risperidone microspheres, QALY quality adjusted life years.
  2. *Total and incremental costs per patient are onsidered as in Table 3.
Back to article page

Annals of General Psychiatry

ISSN: 1744-859X